Fee p.a.
0.95%
ASX report
Fund size
A$99m
12m flow A$-3.1m
Yield
0.8%
1 payments / yr
Volatility 3y
25.2%
annualised
Max DD 3y
−25.2%
all-time −46.2%
Listed
2018
9 Nov 2018 · spread 0.44%
$10k$12k$14k$16k$18k$20k$22k201820192020202120222023202420252026
Performance
Period
Total
ASX
1 month
−0.4%
−4.6%
3 months
1.1%
—
6 months
1.8%
—
Year to date
−1.7%
—
1 year
−1.9%
3.9%
3 years p.a.
5.6%
4.6%
5 years p.a.
−0.9%
−0.8%
10 years p.a.
—
—
Since listing p.a.
7.5%
—
Total return to 4 Sept 2026, distributions reinvested, before franking. ASX figures are to 31 July 2026 and gross of franking, so they run higher for franked Australian funds.
Sharpe 3y 0.07Vol 1y 20.9%Vol 5y 24.5%Max DD 1y −13.2%Max DD 5y −46.2%Best year 40.1%71% positive years
Calendar-year returns
2019
40.1%
2020
26.4%
2021
14.2%
2022
−26.9%
2023
−7.2%
2024
11.6%
2025
15.1%
2026
−1.7%
Where the money is
Look-through exposure as at 3 Sept 2026 · 120 securities · top 10 = 12.2%
Country
China100.0%
Top holdings
Gempharmatech Co LtdChina
1.5%
Wuxi Apptec Co LtdChina
1.4%
Suzhou Sepax Technologies Co LtdChina
1.3%
Harbin Gloria Pharmaceuticals Co LtdChina
1.3%
Haisco Pharmaceutical Group Co LtdChina
1.2%
Aidite Qinhuangdao Technology Co LtdChina
1.1%
Kuaijishan Shaoxing Wine Co LtdChina
1.1%
Guangdong Songfa Ceramics Co LtdChina
1.1%
Guangzhou Ruoyuchen Tech Co LtdChina
1.1%
Shanghai Allist Pharmaceuticals Co LtdChina
1.1%
Zhejiang Cfmoto Power Co LtdChina
1.1%
Suzhou Zelgen Biopharmaceutical Co LtdChina
1.1%
Lancy Co LtdChina
1.1%
Sailun Group Co LtdChina
1.0%
Lotus Holdings Co LtdChina
1.0%
Top 15 of 120 holdings.
Most similar funds
Overlap is the share of the portfolio held in common, look-through. Correlation is of daily returns. High overlap means close substitutes.
Code
Fund
Fee
Overlap
Corr 3y